1,028 reports of this reaction
2.0% of all VORICONAZOLE reports
#8 most reported adverse reaction
BRONCHOPULMONARY ASPERGILLOSIS is the #8 most commonly reported adverse reaction for VORICONAZOLE, manufactured by Roerig. There are 1,028 FDA adverse event reports linking VORICONAZOLE to BRONCHOPULMONARY ASPERGILLOSIS. This represents approximately 2.0% of all 52,026 adverse event reports for this drug.
VORICONAZOLE has an overall safety score of 88 out of 100. Patients taking VORICONAZOLE who experience bronchopulmonary aspergillosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BRONCHOPULMONARY ASPERGILLOSIS is a less commonly reported adverse event for VORICONAZOLE, but still significant enough to appear in the safety profile.
In addition to bronchopulmonary aspergillosis, the following adverse reactions have been reported for VORICONAZOLE:
The following drugs have also been linked to bronchopulmonary aspergillosis in FDA adverse event reports:
BRONCHOPULMONARY ASPERGILLOSIS has been reported as an adverse event in 1,028 FDA reports for VORICONAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BRONCHOPULMONARY ASPERGILLOSIS accounts for approximately 2.0% of all adverse event reports for VORICONAZOLE, making it a notable side effect.
If you experience bronchopulmonary aspergillosis while taking VORICONAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.